Associate Director, Pharmacology

About Parabilis Medicines Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn . What’s the opportunity? We are seeking an experienced industry nonclinical pharmacology leader with a demonstrated track record of advancing oncology programs from discovery through IND submission. This role will serve as the nonclinical pharmacology lead on one or more oncology programs, accountable for nonclinical pharmacology strategy, including translational planning and IND-enabling study design, and contributing to regulatory pharmacology content. You will be expected to meaningfully contribute to regulatory filings and identify translational forward approaches that target early clinical development goals. Your leadership experience and history of working in a highly matrixed cross functional environment will be key in continuing to move oncology programs forward in a collaborative and scientifically rigorous environment. You will work within the existing pharmacology team framework and report directly to the Head of Pharmacology. Success in this role will require excellent communication, scientific thought leadership, a desire to work in a fast paced team environment and an eagerness to grow as a drug hunter. Key abilities of this role include: Lead nonclinical pharmacology strategy for assigned oncology programs from late discovery through IND submission Design, oversee, interpret, and communicate in vivo PK/PD and efficacy studies (internally and via CRO partnerships) Contribute to IND-enabling study design and author or co-author relevant pharmacology sections of regulatory submissions Integrate pharmacology data with DMPK, safety, and biomarker findings to inform development decisions Clearly present data and strategy updates to senior leadership and governance teams Inspire and mentor junior pharmacology team members What you’ll need to be successful: PhD. in Pharmacology, Biology, or related field with 8+ years post-degree experience with a minimum of 2+ years of program leadership and people management experience Experience supporting first-in-class or novel mechanism oncology programs Experience working with small molecules, peptides, degraders (e.g., PROTACs), or biologics Demonstrated success advancing at least one oncology program to development candidate nomination; experience contributing to an IND submission required Strong expertise in in vivo pharmacology , PK/PD modeling concepts, and mechanistic biomarker strategy Proven ability to independently design and interpret studies that support program milestones Demonstrated ability to utilize AI tools for day-to-day work; baseline proficiency is expected, and advanced or innovated use of AI is a strong plus Able to work on-site and attend in-person meetings Enthusiastic and innovative mindset with the ability to thrive in a dynamic, fast-pasted, and highly collaborative environment Excellent communication, organization, multi-tasking, flexibility, and team skil